ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer
Phase III Clinical Trial
Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)